Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Neutral at Cantor Fitzgerald

Cantor Fitzgerald lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from an overweight rating to a neutral rating in a research report released on Wednesday morning, Marketbeat reports. They currently have $36.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $57.00.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $33.05 on Wednesday. The company has a fifty day moving average price of $37.48 and a two-hundred day moving average price of $35.30. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $42,000. Smartleaf Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $52,000. Finally, Headlands Technologies LLC lifted its holdings in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,015 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.